tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Lentigo D007911 1 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Digestive System Fistula D016154 1 associated lipids
Uveitis, Intermediate D015867 3 associated lipids
Miller Fisher Syndrome D019846 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Tumor Lysis Syndrome D015275 2 associated lipids
Autoimmune Diseases of the Nervous System D020274 1 associated lipids
Candidiasis, Vulvovaginal D002181 8 associated lipids
Ecthyma, Contagious D004474 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Chen CH et al. Comparison of tuberculosis infection rates in a national database of renal transplant patients with data from a single center in Taiwan. 2014 Transplant. Proc. pmid:24656019
Nazmul MN et al. Severe Hyperkalemia Complicating Voriconazole Treatment in a Kidney Transplant Recipient With Histoplasmosis: A Case Report. 2017 Transplant. Proc. pmid:29198681
Van Thiel DH et al. Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation. 1990 Transplant. Proc. pmid:1689893
Asselin I et al. Polymerase chain reaction-based assay to assess the success of myoblast transplantation in mdx mice. 1994 Transplant. Proc. pmid:7527970
Azhderian EM et al. Nucleus associated FK 506 binding proteins with potential relevance to FK 506 immunosuppression. 1993 Transplant. Proc. pmid:7679834
Kawauchi M et al. Plasma level of FK 506 in newborn goats and infant baboons. 1991 Transplant. Proc. pmid:1721267
Morozumi K et al. A comparative study of morphological characteristics of renal injuries of tacrolimus (FK506) and cyclosporin (CyA) in renal allografts: are the morphologic characteristics of FK506 and CyA nephrotoxicity similar? 1996 Transplant. Proc. pmid:8623232
Wiesner RH Long-term comparison of tacrolimus versus cyclosporine in liver transplantation. The US FK Study Group. 1998 Transplant. Proc. pmid:9636565
Suzuki K et al. Effect of tacrolimus in renal transplant recipients with immunoglobulin-A nephropathy. 2000 Transplant. Proc. pmid:11119910
Bechstein WO et al. A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients. 2013 Jul-Aug Transplant. Proc. pmid:23953523
Zhao YJ et al. Late, severe, noninfectious diarrhea after renal transplantation: high-risk factors, therapy, and prognosis. 2013 Jul-Aug Transplant. Proc. pmid:23953533
Pedroso JA et al. Elderly kidney transplant recipient with intermittent fever: a case report of leishmaniasis with acute kidney injury during liposomal amphotericin B therapy. 2014 Transplant. Proc. pmid:25242789
Lopes CT et al. Skin allograft survival and analysis of renal parameters after FTY720 + tacrolimus treatment in mice. 2008 Transplant. Proc. pmid:18455036
Thomas FT et al. Comparative efficacy of immunosuppressive drugs in xenografting. 1990 Transplant. Proc. pmid:1693452
Birk PE et al. Preliminary experience with FK 506 in pediatric renal transplant recipients: a single-center report. 1996 Transplant. Proc. pmid:8623493
Nelson PA et al. Effect of immunosuppressive drugs on cytokine gene transcription studied by message amplification phenotyping (MAPPing) polymerase chain reaction. 1991 Transplant. Proc. pmid:1721299
Alloway RR et al. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience. 1996 Transplant. Proc. pmid:8623494
Dumont FJ et al. Up-regulation of gene expression by FK 506. 1991 Transplant. Proc. pmid:1721300
Ciancio G et al. Use of intravenous tacrolimus to reverse vascular rejection in kidney and simultaneous kidney-pancreas transplantation. 1998 Transplant. Proc. pmid:9636624
Bruce DS et al. Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation. 1998 Transplant. Proc. pmid:9636625
Moffatt SD and Metcalfe SM FK 506 versus cyclosporine in combination with anti-CD4/CD8 monoclonal antibodies. 1999 Transplant. Proc. pmid:10578271
Basu A et al. Reversal of acute cellular rejection after renal transplantation with Campath-1H. 2005 Transplant. Proc. pmid:15848576
Töz H et al. Comparison of tacrolimus and cyclosporin in renal transplantation by the protocol biopsies. 2004 Jan-Feb Transplant. Proc. pmid:15013324
Kim SJ et al. A 6-month, multicenter, single-arm pilot study to evaluate the efficacy and safety of generic tacrolimus (TacroBell) after primary renal transplantation. 2009 Transplant. Proc. pmid:19545705
Herrero MJ et al. Clinical interest of pharmacogenetic polymorphisms in the immunosuppressive treatment after heart transplantation. 2010 Transplant. Proc. pmid:20970643
Bachetoni A et al. Preliminary evaluation of the new TACR flex method versus MEIA method in the therapeutic monitoring of tacrolimus in organ transplantation. 2007 Jul-Aug Transplant. Proc. pmid:17692678
Pereira M et al. Hyperacute Rejection in a Kidney Transplant With Negative Crossmatch: A Case Report. 2016 Transplant. Proc. pmid:27742303
Schumacher G et al. Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. 2002 Transplant. Proc. pmid:12176410
Jain A et al. FK 506 in small bowel transplant recipients: pharmacokinetics and dosing. 1994 Transplant. Proc. pmid:7518149
Hatazawa C et al. Effect of FK 506 on bowel transplantation in rats. 1992 Transplant. Proc. pmid:1376517
Zeevi A et al. Serial evaluation of immune profiles of simultaneous bone marrow and whole organ transplant recipients. 1995 Transplant. Proc. pmid:7533388
Kawauchi M et al. Flow cytometric analysis of lymphocyte populations in FK 506-treated newborn goats. 1991 Transplant. Proc. pmid:1721331
Izuishi K et al. Effect of an immunosuppressive agent, tacroliums (FK-506), on the activities of cytochrome P-450-linked monooxygenase systems of rat liver microsomes. 2003 Transplant. Proc. pmid:12591538
Kindt MV et al. Tacrolimus toxicity in rhesus monkey: model for clinical side effects. 1999 Transplant. Proc. pmid:10616519
Gaston RS Potential utility of rapamycin and tacrolimus in long-term, low-toxicity regimens. 1999 Transplant. Proc. pmid:10616556
Yoshimura N et al. Safety analysis after tacrolimus immunosuppression in renal transplant recipients in Japan: 5-year results in >1500 patients. 2005 Transplant. Proc. pmid:15919458
Sugitani A et al. Long-term results of tacrolimus therapy for renal transplantation in patients with diabetic nephropathy in Japan. 2005 Transplant. Proc. pmid:15919459
Hayes D et al. Aerosolized tacrolimus: a case report in a lung transplant recipient. 2010 Transplant. Proc. pmid:21094875
Kobayashi M et al. Posttransplant donor-specific T-lymphocytotoxic antibody in liver transplant patients with a positive crossmatch. 1992 Transplant. Proc. pmid:1281570
Lemster B et al. Cytokine gene expression in murine lymphocytes activated in the presence of FK 506, bredinin, mycophenolic acid, or brequinar sodium. 1992 Transplant. Proc. pmid:1281576
Takahashi N et al. Nitric oxide generation in renal allograft recipients. 1998 Transplant. Proc. pmid:9838306
Japanese study of FK 506 on kidney transplantation: results of an early phase II study. Japanese FK 506 Study Group. 1991 Transplant. Proc. pmid:1721363
Chamienia A et al. One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus. 2006 Jan-Feb Transplant. Proc. pmid:16504670
van Hoek B et al. Recurrence of ductopenic rejection in liver allografts after retransplantation for vanishing bile duct syndrome. 1991 Transplant. Proc. pmid:1703343
Gregory CR Immunosuppressive approaches to the prevention of graft vascular disease. 1998 Transplant. Proc. pmid:9595134
Gentil MA et al. Safety and efficacy of delayed introduction of low-dose tacrolimus in elderly recipients of cadaveric renal transplants from donors over 55 years of age. 2003 Transplant. Proc. pmid:12962766
Sellers M et al. Incidence of late acute rejection and progression to chronic rejection in pediatric liver recipients. 1997 Feb-Mar Transplant. Proc. pmid:9123065
Costa A et al. Stimulatory effect of FK506 and erythromycin on pig intestinal motility. 1996 Transplant. Proc. pmid:8907957
Garcia I Efficacy and safety of dual versus triple tacrolimus-based therapy in kidney transplantation: two-year follow-up. 2002 Transplant. Proc. pmid:12176516
Youbin Z et al. Tumor Necrosis Factor-α-Induced Protein 8-Like 2 Gene Overexpression Prolongs the Survival of Rat Allogeneic Heart Allografts. 2015 Transplant. Proc. pmid:26518962
Song Z et al. FK 506 prevents islet xenograft rejection: a study in the pig-to-rat model. 1999 Feb-Mar Transplant. Proc. pmid:10083437
Navia MA Rational design of new immunosuppressive drugs. 1999 Feb-Mar Transplant. Proc. pmid:10083489
Gudas VM et al. Comparison of the immunosuppressive and toxic effects of FK506 and cyclosporine in xenograft recipients. 1989 Transplant. Proc. pmid:2468211
Carroll PB et al. FK 506-associated diabetes mellitus in the pediatric transplant population is a rare complication. 1991 Transplant. Proc. pmid:1721396
Sato K et al. Pancreaticoduodenal allotransplantation with cyclosporine and FK506. 1989 Transplant. Proc. pmid:2468212
Freise CE et al. Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient. 1991 Transplant. Proc. pmid:1721397
Hsu KH et al. Combined sirolimus-calcineurin inhibitor immunosuppressive therapy in simultaneous heart and kidney transplantation: a retrospective analysis of a single hospital's experience. 2010 Transplant. Proc. pmid:20430208
Tsao CI et al. Unplanned readmission within 1 year after heart transplantation in Taiwan. 2010 Transplant. Proc. pmid:20430212
Stratta RJ Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: a multi-center report. The FK/MMF Multi-Center Study Group. 1997 Feb-Mar Transplant. Proc. pmid:9123463
Gruessner AC et al. Solitary pancreas transplants: improving results and factors that influence outcome. 1997 Feb-Mar Transplant. Proc. pmid:9123468
Mohacsi P et al. Immunosuppression in ABO-incompatible transplantation. 2001 Transplant. Proc. pmid:11377508
Artz MA et al. Randomized conversion from cyclosporine to tacrolimus in renal transplant patients: improved lipid profile and unchanged plasma homocysteine levels. 2002 Transplant. Proc. pmid:12176579
Jonas S et al. Corticosteroid-free therapy after tacrolimus-based dual immunosuppression versus cyclosporine-based quadruple-induction therapy. 2001 Transplant. Proc. pmid:11377511
Boucher A et al. Impact of immunosuppressive regimen on cardiovascular risk factors in kidney transplant recipients. 2002 Transplant. Proc. pmid:12176582
Saber LT et al. Posttransplantation conversion to sirolimus-based immunosuppression: a single center experience. 2007 Transplant. Proc. pmid:18089330
Chung YW et al. Tacrolimus-Induced Apoptosis is Mediated by Endoplasmic Reticulum-derived Calcium-dependent Caspases-3,-12 in Jurkat Cells. 2018 Transplant. Proc. pmid:29731088
Dudley CR Conversion at first rejection: a prospective trial comparing cyclosporine microemulsion with tacrolimus in renal transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267179
Takeda Y et al. Effect of FK 506 on the survival of rat small bowel allografts. 1991 Transplant. Proc. pmid:1721426
Kokado Y et al. Hypertension in renal transplant recipients and its effect on long-term renal allograft survival. 1996 Transplant. Proc. pmid:8658802
Tamura K et al. A highly sensitive method to assay FK-506 levels in plasma. 1987 Transplant. Proc. pmid:2445069
Falkenstein K and Dunn S Tacrolimus to cyclosporine microemulsion formulation conversion in the pediatric liver transplant patient. 1998 Transplant. Proc. pmid:9723354
Eun SC et al. Prolongation of the rat composite tissue allograft survival by the combination of tolerogenic immature dendritic cells and short-term treatment with FK506. 2013 Transplant. Proc. pmid:23769045
Li Y et al. Long-term comparison of rat model of chronic allograft rejection of orthotopic small bowel transplantation induced by cyclosporine versus tacrolimus. 2013 Transplant. Proc. pmid:23769050
Liu W et al. Transfusion of endothelial cells with lentivirus-mediated expression of fas ligand prolonged survival of rat liver allograft. 2012 Transplant. Proc. pmid:22664023
Ishida S et al. Calcineurin Inhibitor-Induced Pain Syndrome in ABO-Incompatible Living Kidney Transplantation: A Case Report. Transplant. Proc. pmid:28104127
Asensio M et al. Induction with basiliximab reduces acute rejection in pediatric liver transplant patients treated with tacrolimus and steroids. 2002 Transplant. Proc. pmid:12176650
Sindhi R et al. Preliminary immunosuppression withdrawal strategies with sirolimus in children with liver transplants. 2002 Transplant. Proc. pmid:12176651
Kandaswamy R et al. Can we maintain immunosuppression avoiding nephrotoxic agents in pancreas transplantation? 2008 Transplant. Proc. pmid:18374118
Matevossian E et al. Nitric oxide inhibition and consecutive Aspisol application show a prolonged survival of orthotopic transplanted livers in a rat model. 2008 Transplant. Proc. pmid:18555092
Kanodia KV et al. Study of acute antibody-mediated rejection in renal allograft biopsies. 2008 Transplant. Proc. pmid:18555123
Kattner A et al. Conversion from CyA to CyA-NOF in a cholestatic liver grafted patient with CyA malabsorption. 1994 Transplant. Proc. pmid:7524225
Pirenne J et al. Standard cyclosporine A-based versus completely steroid-free FK506-based immunosuppression after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267396
Fung JJ and Starzl TE FK 506 in solid organ transplantation. 1994 Transplant. Proc. pmid:7524226
Langrehr JM et al. A prospective, randomized trial with quadruple versus dual tacrolimus-based induction after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267404
Carroll PB et al. The use of FK 506 in new-onset type I diabetes in man. 1991 Transplant. Proc. pmid:1721458
McCauley J et al. FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome. 1991 Transplant. Proc. pmid:1721459
Wakabayashi H et al. Effect of FK 506 and cyclosporine A on hepatic energy status in the rat after warm ischemia, as monitored by 31P nuclear magnetic resonance spectroscopy in vivo. 1992 Transplant. Proc. pmid:1384205
Toki K et al. Histopathologic findings in routine biopsies of renal transplant allografts. 1999 Transplant. Proc. pmid:10500759
Griffin AD et al. FK 506 in canine renal transplantation. 1992 Transplant. Proc. pmid:1384209
Silber RE et al. Comparison of the effect of FK 506 and alpha/beta-T-cell antibody R73 on transplant vascular sclerosis after heterotopic rat heart transplantation. 1998 Transplant. Proc. pmid:9636398
Nichelle L et al. Arterial hypertension in renal transplant recipients treated with tacrolimus or cyclosporine-Neoral. 2002 Transplant. Proc. pmid:12431623
Ciancio G et al. Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation. 2010 Transplant. Proc. pmid:21094804
Teng D et al. Comparison of rapamycin versus FK506 on expression of cytoprotective genes in the rat kidney allografts undergoing chronic allograft nephropathy. 2006 Transplant. Proc. pmid:16980034
Keshavamurthy M et al. Single-center study utilizing C(2) level as monitoring tool in de novo renal transplant recipients treated with Neoral. 2001 Nov-Dec Transplant. Proc. pmid:11750338
Bing P et al. Comparison of expression of TGF-beta1, its receptors TGFbeta1R-I and TGFbeta1R-II in rat kidneys during chronic nephropathy induced by cyclosporine and tacrolimus. 2006 Transplant. Proc. pmid:16980036
Hildebrandt A et al. FK 506: short- and long-term treatment after cardiac transplantation in nonhuman primates. 1991 Transplant. Proc. pmid:1703694
Ericzon BG et al. Effect of FK 506 on glucose metabolism in the cynomolgus monkey: studies in pancreatic transplant recipients and nontransplanted animals. 1991 Transplant. Proc. pmid:1703695
Friemann S et al. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. 1998 Transplant. Proc. pmid:9636504
Fernando ON et al. Elective conversion of patients from cyclosporine to tacrolimus for hypertrichosis. 1998 Transplant. Proc. pmid:9636505
Nakamura A et al. Effects of elevated tacrolimus trough levels in association with infectious enteritis on graft function in renal transplant recipients. 2014 Transplant. Proc. pmid:24656020